Merck & Co. (NYSE: MRK) beats Q3-FY2026 EPS consensus of $2.13 per share — quarterly report October 29, 2026 before market open (confirmed by Merck Investor Relations or Bloomberg by October 29, 2026, 12:00 PM ET)
Hit
✦ AI-generated prediction
Published on 26. October 2026
·
Predicted for 29. October 2026
·
Based on: Historical Cycle
Merck reports on October 29, 2026 before market open. Consensus EPS per earnings calendar: $2.13. Keytruda (pembrolizumab) remains the world's best-selling cancer drug and primary revenue driver. Historical FactSet data shows a ~83% hit rate (approximately 10 out of 12 quarters with EPS beat) for Merck. Despite ongoing IRA price negotiations and patent cliff risks from 2028, Q3 core business remains stable. No direct Polymarket market for this report. The high historical hit rate and structural Keytruda strength justify a probability of 63–67%.
Data basis for this prediction
- Stocktitan Earnings Calendar: Merck & Co. Q3 FY2026, 29. Oktober 2026 BMO, Konsens EPS 2,13 USD (stocktitan.net, Stand Oktober 2026)
- FactSet Earnings Insight historisch: Merck ~83% EPS-Beat-Rate in letzten 12 Quartalen
- Merck Investor Relations: Keytruda als Nr.-1-Umsatztreiber und primärer Wachstumsmotor (MRK IR, 2026)
Note: This is an AI-generated statistical forecast for entertainment and information purposes. It does not constitute investment advice or a recommendation to buy or sell any financial instrument.
Verdict: Hit
[Vorzeitig entschieden] Merck berichtete bereinigtes EPS von 2,19 USD und übertraf damit den Konsens von 2,13 USD. Quelle: MarketBeat, NASDAQ
📈 Economy
✦ AI
Gold (XAU/USD) rose to $4,134.83 on 5 November 2026 — driven by the Democratic midterm sweep (higher fiscal spending expected) and persistent inflation pressure. Kalshi's Dec 31 settlement market shows ~32% probability for a close above $4,400 and ~43% for above $4,300. Reaching the $4,400 year-end target would require a further ~6.4% gain. Supporting factors: fiscal expansion, geopolitical risks, structurally high central bank demand; UBS forecasts $4,800, JPMorgan $6,000 at year-end. Headwind: hawkish Fed stance (Polymarket: 72.5% for a December rate hike to 4.00–4.25%). Prediction anchors on Kalshi's ~32% for >$4,400.
📈 Economy
✦ AI
Gold traded at approximately $4,130 per troy ounce on November 5, 2026 — a one-day gain of +1.68% (+$66) following the Democratic midterm sweep (Democrats won both the Senate and the House, per AP/NBC, November 5, 2026). Polymarket prices a 49% probability of gold exceeding $4,200 in November (as of November 5, 2026). The target is only 1.7% above today's closing level with 25 trading days remaining. Upside drivers: Iran de-escalation by new Democratic Congress, falling oil prices (WTI −1.13% to $87.13). Risk factors: profit-taking, rising real yields.
📈 Economy
✦ AI
Cisco has beaten Non-GAAP EPS consensus in 7 of its last 8 quarters. For Q1 FY2027 (August–October 2026) the company itself guided $1.32–$1.34 per share — the market consensus of $1.32 sits at the bottom of this self-guided range, which historically signals a beat for Cisco (Q4 FY2026: $1.22 vs. consensus $1.17). AI-networking growth, Splunk integration synergies, and record Q4 FY2026 revenue ($17.25B) confirm the structural growth momentum. Q1 FY2027 revenue consensus: $18.11B (within guidance range $18.0–18.2B).